DNA damage response
Targeting the DNA repair process to block tumour cells' ability to reproduce
What is DNA damage response and why is it important?
DNA Damage Response Inhibition is an innovative new anti-cancer platform which could revolutionise the treatment of cancer. It works by exploiting DNA Damage Response defects which are specific to cancer cells, and kills them whilst sparing normal cells.1
AstraZeneca is pioneering this new treatment paradigm. We believe it is a crucial step forward in our aim of one day eliminating cancer as a cause of death.
The science behind DNA Damage Response Inhibition
Every day, DNA in our cells is damaged thousands of times by natural causes and external factors. If not corrected, this DNA damage could eventually lead to cancer.1 The body has developed systems to protect the cells from DNA damage, called the DNA Damage Response or DDR.1
A faulty DNA Damage Response system helps cancer develop, as it allows mutations that promote uncontrolled cell growth.2 Cancer cells with a DNA Damage Response deficiency are heavily reliant on remaining ‘back up’ DNA Damage Response systems.1
DNA Damage Response Inhibition exploits these defects by blocking the remaining response systems cancer cells are relying on to survive, which in turn causes them to die. Healthy cells are not vulnerable to this type of treatment.1
What we're working on
AstraZeneca is committed to investigating the potential of DNA Damage Response Inhibition across a range of tumour types. We currently have five compounds being investigated in clinical trials. The mechanism of action of DNA Damage Response Inhibitors suggests that they can be combined with other DNA Damage Response Inhibitors, immuno-oncology agents and targeted therapies.
Inhibiting damage repair
The PARP (Poly ADP-ribose polymerase) protein repairs single strand breaks in DNA, which if unrepaired can lead to double strand breaks.1 Some cancers, such as those caused by BRCA mutations (including breast, ovarian, prostate and pancreatic cancers)2 cannot repair double strand breaks and rely on PARP to repair single strand breaks.1 Blocking PARP can force single strand breaks to become double strand breaks, and as there is no reliable system left to repair them, they accumulate and the cancer cell dies.1
AstraZeneca launched the first PARP inhibitor, olaparib, which is licensed in BRCA mutated ovarian cancer, and is currently being investigated in a number of other tumour types.
Blocking cell growth and replication
Wee1 is a protein kinase that helps to regulate the cell cycle by pausing it after DNA damage occurs, allowing cells time to repair the damage.3 Wee1 is overexpressed in many breast,3 lung,4 and colon cancers,3 suggesting that the tumour relies heavily on this mechanism to survive. By inhibiting Wee1, the cell cycle continues without pausing, and the DNA damage isn’t repaired which leads to tumour cell death.3
AstraZeneca is currently investigating a potent and selective Wee1 inhibitor across several Phase I and Phase II trials in solid tumours.
Preventing damage being detected
Ataxia telangiectasia and rad3 related (ATR) and Ataxia telangiectasia mutated (ATM) kinases are proteins involved in detecting DNA damage, stabilising the DNA and recruiting the appropriate proteins to fix the damage when DNA replication stalls.5 Inhibition of ATR or ATM can prevent damage from being detected or repaired, as well as allowing it to be carried over into the next phase of the cell cycle.6 This leads to an accumulation of damage, and ultimately, cell death.6
AstraZeneca’s pipeline currently includes both ATM and ATR inhibitors in Phase I development.
1. O’Connor M, ‘Targeting The DNA Damage Response In Cancer’ (2015) 60 Molecular Cell
2. Jackson S and Bartek J, ‘The DNA-Damage Response In Human Biology And Disease’ (2009) 461 Nature
3. Vriend L and others, ‘WEE1 Inhibition And Genomic Instability In Cancer’ (2013) 1836 Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
4. De Witt Hamer P and others, ‘WEE1 Kinase Targeting Combined With DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe’ (2011) 17 Clinical Cancer Research
5. A. Maréchal and L.Zou, ‘DNA Damage Sensing by the ATM and ATR Kinases’ (2013) Cold Spring Harb Perspect Biol
6. Weber A and Ryan A, ‘ATM And ATR As Therapeutic Targets In Cancer’ (2015) 149 Pharmacology & Therapeutics
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
Veeva ID: Z4-4978
Date of next review: May 2018